Beclometasone (Salbair B Forte) inhalation powder contains beclomethasone dipropionate, which is a synthetic steroid derivative. The clinical efficacy of beclomethasone dipropionate in the treatment of asthma is based on its strong topical anti-inflammatory Activity on the mucosa of the lungs. Inhaled beclomethasone dipropionate has not been found to have the systemic effects typical of steroids at daily doses <1500 mcg. Long-term studies have shown that after the initiation of inhaled beclomethasone dipropionate in patients with bronchial asthma, the dose of systemic corticosteroids may be constantly reduced. There is no evidence that Beclometasone (Salbair B Forte) would damage tracheobronchial mucosa or increase the incidence of respiratory infections. Approximately 10-25% of the inhaled drug dose reaches the lungs and the biggest fraction of the dose is retained in the upper airways and mouth and is swallowed. Beclometasone (Salbair B Forte) treatment should be regular because the beneficial effects of the medication will appear only after a few days' use and the maximal effect will be attained only after several weeks. Beclomethasone dipropionate has no effect in an acute attack. When shifting from freon-based metered dose aerosols to inhalation powders, it is optimal to choose a dispenser, which is used in the same way as the patient's previous inhaler except for the hand-lung coordination. Also similarity of the drug doses between the new and previous dispenser is an advantage to the patient. The clinical efficacy and tolerability of Beclometasone (Salbair B Forte) are the same as those of a corresponding dose of beclomethasone dipropionate from a freon-based inhalation aerosol given through an inhalation chamber.